Esperion Therapeutics, Inc.
Explore Esperion Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
ESPR — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zoetis Inc. | $79.44 | 12.31 | $32.53 B | 1.64% | 27.18% | 62.41% | $171.52 / $72.38 | $7.84 |
| 2. | United Therapeutics Corporation | $549.87 | 18.12 | $23.32 B | — | 20.73% | 19.24% | $609.35 / $272.12 | $162.6 |
| 3. | Viatris Inc. | $15.88 | — | $18.12 B | 3.09% | 0.84% | -1.97% | $17.53 / $8.44 | $12.78 |
| 4. | Neurocrine Biosciences, Inc. | $163.88 | 24.8 | $16.58 B | — | 16.37% | 21.64% | $169.57 / $122.14 | $32.5 |
| 5. | Elanco Animal Health Incorporated | $23.63 | — | $11.8 B | — | 2.14% | -3.64% | $27.72 / $13.16 | $13.17 |
| 6. | Dr. Reddy's Laboratories Limited | $13.24 | 25.19 | $11.1 B | 0.01% | — | 4.24% | $14.49 / $12.06 | $4.23 |
| 7. | Alkermes plc | $42.8 | 47.15 | $7.2 B | — | 13.07% | 8.82% | $44.57 / $25.17 | $10.99 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 168.45 M | 87.31 M | 82.39 M | 65 M | 69.11 M | — |
| Operating Profit | 85.23 M | -9.96 M | 7.09 M | -22.1 M | -4.42 M | — |
| Net Profit | 61.83 M | -31.33 M | -12.72 M | -40.45 M | -21.32 M | — |
| EPS in Rs | 0.24 | -0.12 | -0.05 | -0.16 | -0.08 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 403.13 M | 332.31 M | 116.33 M | 75.47 M |
| Operating Profit | 60.27 M | 54.4 M | -155.56 M | -179.5 M |
| Net Profit | -22.68 M | -51.74 M | -209.25 M | -233.66 M |
| EPS in Rs | -0.09 | -0.2 | -0.81 | -0.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 465.89 M | 343.82 M | 205.8 M | 247.94 M |
| Total Liabilities | 767.85 M | 732.54 M | 660.79 M | 571.72 M |
| Equity | -301.96 M | -388.72 M | -454.99 M | -323.78 M |
| Current Assets | 462.57 M | 338 M | 201.06 M | 246.68 M |
| Current Liabilities | 300.81 M | 246.23 M | 156.22 M | 92.31 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.09 M | -23.65 M | -135.49 M | -174.83 M |
| Investing CF | 0 M | -0.32 M | 42.5 M | 8.1 M |
| Financing CF | 36.18 M | 86.48 M | 50.46 M | 32.61 M |
| Free CF | -13.09 M | -23.97 M | -135.49 M | -174.83 M |
| Capex | — | -0.32 M | — | — |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 21.31% | 185.66% | 54.14% | — |
| Earnings Growth % | 56.17% | 75.27% | 10.45% | — |
| Profit Margin % | -5.63% | -15.57% | -179.87% | -309.58% |
| Operating Margin % | 14.95% | 16.37% | -133.72% | -237.83% |
| Gross Margin % | 67.95% | 79.36% | 62.81% | 64.27% |
| EBITDA Margin % | 15.84% | 2.28% | -129.03% | -233.65% |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — Esperion Therapeutics, Inc.
Will Esperion Therapeutics, Inc. stock hit $4 in 2026?
Esperion Therapeutics, Inc. (ESPR) is currently trading at $3.13, with a 52-week range of $0.95 to $4.18. Reaching the $4 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Wall Street analysts currently have a consensus price target of $6.74 for Esperion Therapeutics, Inc., with a Buy rating, and the most bullish analysts see the stock reaching as high as $16.0. Whether Esperion Therapeutics, Inc. can reach $4 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, ESPR has delivered a -30.9% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the ESPR Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Esperion Therapeutics, Inc. stock worth buying at $3.13?
Whether Esperion Therapeutics, Inc. (ESPR) is worth buying at $3.13 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency: Esperion Therapeutics, Inc. has a Return on Capital Employed (ROCE) of 36.5%, which indicates the business is generating strong returns on the capital it deploys — a hallmark of a high-quality business. Its Return on Equity (ROE) stands at -59.5%.
Financial health: The Debt-to-Equity ratio of -0.84 indicates a conservative balance sheet with more equity than debt, reducing financial risk.
Analyst view: The Wall Street consensus recommendation for ESPR is currently Buy, with a mean price target of $6.74 based on 8 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Esperion Therapeutics, Inc. (ESPR) in 2026?
As of 2026, Wall Street analysts have set a consensus (mean) price target of $6.74 for Esperion Therapeutics, Inc. (ESPR), aggregated from 8 analyst ratings. The overall analyst recommendation is Buy.
The price target range spans from $1.78 on the bearish end to $16.0 on the most optimistic projection, with a median target of $5.08. This wide range reflects differing views on Esperion Therapeutics, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.
It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the ESPR analysis page on StockSifting.
What will Esperion Therapeutics, Inc. stock be worth in 2029?
Projecting Esperion Therapeutics, Inc. (ESPR)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
Based on ESPR's historical 5-year Compound Annual Growth Rate (CAGR) of -30.9%, if that rate of growth were to continue, the stock could reach approximately $1 by 2029 — up from its current price of $3.13. This projection assumes the historical CAGR holds, which depends on Esperion Therapeutics, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the ESPR Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.